Vnitr Lek 2014, 60(4):327-330

Impact of galectin 3 as myofibrosis marker in clinical cardiology

Filip Málek
Kardiovaskulární centrum Nemocnice Na Homolce Praha, přednosta prim. MUDr. Ivo Skalský, MBA

Galectin 3 is a protein secreted by activated macrophages and has a role in development of fibrosis in injured tissues. Experimental studies showed increased galectin 3 secretion in the context of cardiac hypertrophy and heart failure models. Several clinical studies identified galectin 3 to be a biomarker of cardiovascular diseases in the field of diagnosis, risk stratification, monitoring therapy response and predicting short-term and long-term prognosis. Particularly, the additional prognostic information of galectin 3 as assessed together with NT-proBNP was established in acute and chronic heart failure.

Keywords: galectin 3; heart failure; myofibrosis; outcome prediction

Received: January 14, 2014; Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Impact of galectin 3 as myofibrosis marker in clinical cardiology. Vnitr Lek. 2014;60(4):327-330.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Braumwald E. Biomarkers in heart failure. New Engl J Med 2008; 358(20): 2148-2159. Go to original source... Go to PubMed...
    2. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41(3): 532-543. Go to original source... Go to PubMed...
    3. Málek F. Arteriální hypertenze a chronické srdeční selhání. Cor et Vasa 2013; 55(3): 325-329. Go to original source...
    4. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interexpression and NADPH oxidase activity are increased in aortas from stitium. Fibrosis and renin-angiotensin-aldosterone system. Circu-hypertensive rats. Circulation 1991; 83(6): 1849-1865. Go to original source... Go to PubMed...
    5. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: E17. Dostupné z DOI: <http://doi:10.1017/S1462399408000719>. Go to original source... Go to PubMed...
    6. Barboni EA, Bawumia S, Henrick K et al. Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding. Glycobiology 2000; 10(11): 1201-1208. Go to original source... Go to PubMed...
    7. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Res Reports Clin Cardiol 2013; 4: 13-22. Go to original source...
    8. Nieminen J, St-Pierre C, Bhaumik P et al. Role of galetin-3 in leukocyte recruitement in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 2008; 180(4): 2466-2473. Go to original source... Go to PubMed...
    9. Gupta SK, Masinick S, Garrett M et al. Pseudomonas aeruginosa lipopolysacharide binds galectin-3 and other human corneal epithelial proteins. Infect Immun 1997; 65(7): 2747-2753. Go to original source... Go to PubMed...
    10. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110(19): 3121-3128. Go to original source... Go to PubMed...
    11. Schroen B, Heymans S, Sharma U et al. Thrombospondin-2 is Essentials for myocardial matrix integrity: increased expression identifies silure-prone cardiac hypertrophy. Circ Res 2004; 95(5): 515-522. Go to original source... Go to PubMed...
    12. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in Cardiac Remodeling and Heart Failure. Curr Heart Fail Rep 2010; 7(1): 1-8. Go to original source... Go to PubMed...
    13. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103(13): 5060-5065. Go to original source... Go to PubMed...
    14. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue Indry. J Biol Chem 2000; 275(4): 2247-2250. Go to original source... Go to PubMed...
    15. Henderson NC, Mackkinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172(2): 288-298. Go to original source... Go to PubMed...
    16. Nishi Y, Sano H, Kawashima T et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007; 56(1): 57-65. Go to original source... Go to PubMed...
    17. Wang L, Friess H, Zhu Z et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 2000; 80(8): 1233-1241. Go to original source... Go to PubMed...
    18. de Boer RA, Voors AA, Muntendam P et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11(9): 811-817. Go to original source... Go to PubMed...
    19. van Kimmenade RR, Januzzi jr. JL, Ellinor PT et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Col Cardiol 2006; 48(6): 1217-1224. Go to original source... Go to PubMed...
    20. Kjekshus J, Apetrei E, Barrios V et al (for the CORONA Group). Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357(22): 2248-2261. Go to original source... Go to PubMed...
    21. Cleland JGF, Daubert JC, Erdmann E et al. The Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352(15): 1539-1549. Go to original source... Go to PubMed...
    22. Gullestad L, Ueland T, Kjekshus J et al. CORONA Study Group Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33(18): 2290-2296. Go to original source... Go to PubMed...
    23. Lopez-Andrès N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14(1): 74-81. Go to original source... Go to PubMed...
    24. Januzzi jr. JL, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95(8): 948-954. Go to original source... Go to PubMed...
    25. Jaarsma T, van der Wal MHL, Lesman-Leegte I et al (for the coordinating study evaluating outcomes of advising and counseling in heart failure - COACH). Effect of moderate or intensive disease management on outcome in patients with heart failure. Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Int Med 2008; 168(3): 316-324. Go to original source... Go to PubMed...
    26. Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from DEAL-HF study. Clin Res Cardiol 2010; 99(5): 323-328. Go to original source... Go to PubMed...
    27. Lok DJ, van der Meer P, de La Porte PB et al. Galectin-3, a Novel Marker of Macrophage Activity, Predicts Outcome in Patients With Stable Chronic Heart Failure. J Am Coll Cardiol 2007; 49(9 Suppl 1): 98A.
    28. de Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43(1): 60-68. Go to original source... Go to PubMed...
    29. de Boer RA, va Veldhuisen DJ, Gansevoort RT et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272(1): 55-64. Go to original source... Go to PubMed...
    30. Ho JE, Liu Ch, Lyass A et al. Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. J Am Coll Cardiol 2012; 60(14): 1249-1256. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.